Biotech: Page


  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data

    Replimune shares plummeted 40% on concerns FDA scientists are still skeptical of its melanoma drug. Elsewhere, investors had a muted reaction to a first-of-its-kind study result.

    By BioPharma Dive staff • July 29, 2026
  • A red magnifying glass sits on top of cash.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    An eye drug biotech banks $118M and stocks its executive suite

    Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.

    By • July 28, 2026
  • Explore the Trendline➔
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip
    Trendline

    Emerging biotech

    New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

    By BioPharma Dive staff
  • Abstract financial graph with up trend line on neon light colour background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Brain drug revival

    MapLight dives despite positive data for schizophrenia drug

    Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers' Cobenfy.

    By • July 27, 2026
  • Pills lie on top of hundred dollar bills.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug

    The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among multiple developers.

    By • July 27, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    FDA scientists question Capricor data; Legend CEO steps down

    Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipeline trouble.

    By • July 27, 2026
  • Podcast promo image with a vintage microphone, featuring Almac and BioPharma Dive logos and the title “From Protocol to Patient: Inside Clinical Supply.”
    Image attribution tooltip
    Almac Clinical Services/BioPharma Dive
    Image attribution tooltip
    Sponsored by Almac Clinical Services

    [Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Services

    This podcast explores how clinical trial supplies move from early planning to global delivery, ensuring investigational medicines reach patients safely and on time.

    By BioPharma Dive's studioID • Updated May 26, 2026
  • Colleagues using an ipad
    Image attribution tooltip
    Permission granted by ICON plc
    Image attribution tooltip
    Sponsored by ICON

    From confidence to capital: Positioning biotech for the next growth cycle

    How can biotechs be investor ready? Key takeaways from BIO International and DIA China 2026.

    By Deepali Suri, President, ICON Biotech • July 27, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma

    Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.

    By BioPharma Dive staff • July 24, 2026
  • Close up of Wall Street sign, with tall buildings in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Scribe secures $129M in a rare gene editing IPO

    The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotechs that have gone public in 2026.

    By • July 23, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study

    A new analysis could address some doubts investors have had about ivonescimab, one analyst said. Elsewhere, Gilead and Merck debuted data for a once-weekly HIV tablet and a new pyschedelics competitor emerged.

    By • July 22, 2026
  • A person cradles their foot at the metatarsophalangeal joints.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Crystalys nets $130M more to push gout drug through late-stage tests

    The startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t yet available in the U.S. or Europe.

    By • July 22, 2026
  • An illustration of sickled red blood cells.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Agios scraps sickle cell drug

    The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.

    By • July 21, 2026
  • A photo of the three founders of Dimension
    Image attribution tooltip
    Permission granted by Dimension
    Image attribution tooltip
    Emerging biotech

    Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’

    The young venture firm, which has bet heavily on tech and biotech’s convergence, has now invested in 35 companies and recently saw one of them acquired by AI giant Anthropic.

    By • July 21, 2026
  • Front view of the NASDAQ MarketSite, which occupies the northwest corner at the base of the 4 Times Square building, in Midtown Manhattan, New York City.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Pain drugmaker Latigo outlines plans to go public

    The Westlake-founded company specializes in non-opioid drugs that target sodium ion channels, and is now adding to what’s already been a busy month for the biotech IPO queue.

    By • July 20, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker

    Bristol Myers is the third pharmaceutical company to recently seek Nvidia’s help building a large AI data center. Elsewhere, a Novartis kidney drug gained a leg up on competitors.

    By • July 20, 2026
  • Pills lie on top of hundred dollar bills.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Jasper gets a lifeline in merger with immune drugmaker Kira

    The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from setbacks that have wiped out most of its market value.  

    By • July 17, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances

    The new lawsuits add to a web of legal disputes over technology involved in COVID vaccines. Elsewhere, a prolific AI biotech inked another deal and Insmed strengthened support for a closely watched blood pressure drug.

    By BioPharma Dive staff • July 17, 2026
  • robot hand
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    How well are AI-discovered drugs faring in the clinic?

    Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.

    By Kelly Bilodeau • July 17, 2026
  • A photo of the street sign for Wall Street, in front of a row of American flags.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Braveheart, Attovia join next wave of biotech IPOs

    The heart drug developer and immune disease specialist aim to capitalize on momentum that’s already yielded several big-ticket IPOs this year.

    By • July 15, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals

    J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.

    By • July 15, 2026
  • The exterior of the Law Courts Building in the Cayman Islands.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Judge orders Apple Tree partner to forfeit oversight of venture fund

    The ruling from a Cayman Islands court adds a new wrinkle to an ongoing legal dispute that’s already resulted in a bankruptcy filing — and a bid by general partner Seth Harrison for the firm’s portfolio companies.

    By • Updated July 14, 2026
  • A candlestick stock chart is seen out of focus against a background of $100 dollar bills in this composite stock image.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Draig bags another $65M to speed testing of brain drugs

    The cash will support mid-stage trials of a prospect the company claims to have “best-in-disease” potential treating major depressive disorder. 

    By • July 14, 2026
  • An illustration of beta amyloid plaques and tau in the brain
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
    Image attribution tooltip
    Brain drug revival

    Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugs

    The study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.

    By • July 14, 2026
  • A colorful stock market ticker
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Q32 bounces back to claim study success for alopecia drug

    Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations. 

    By • July 13, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    Agenus surges on study pivot; Apnimed lines up an IPO

    Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.

    By • July 13, 2026